Conbercept
- Generic Name
- Conbercept
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1227158-72-6
- Unique Ingredient Identifier
- 1P05PW62F3
- Background
Conbercept has been investigated for the basic science of Age-related Macular Degeneration.
- Indication
用于治疗湿性年龄相关性黄斑变性(AMD)。
- Associated Conditions
- -
- Associated Therapies
- -
Efficacy and Safety of Low-dose Conbercept for Retinopathy of Prematurity Therapy
- Conditions
- Interventions
- First Posted Date
- 2024-12-05
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Wang Yusheng
- Target Recruit Count
- 146
- Registration Number
- NCT06717412
Efficacy and Safety of Conbercept for Diabetic Macular Edema Combined With Severe Non-proliferative Diabetic Retinopathy
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2024-07-23
- Target Recruit Count
- 58
- Registration Number
- NCT06305143
- Locations
- 🇨🇳
Shanghai Eye Diseases Prevention &Treatment Center, Shanghai, Shanghai, China
Conbercept for Polypoidal Choroidal Vasculopathy（START Study）
- Conditions
- First Posted Date
- 2022-02-08
- Last Posted Date
- 2022-02-08
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 500
- Registration Number
- NCT05229237
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
Anti-VEGF in Real-world
- First Posted Date
- 2022-02-03
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Wenbin Wei
- Target Recruit Count
- 1000
- Registration Number
- NCT05222633
- Locations
- 🇨🇳
Wen-Bin Wei, Beijing, Beijing, China
Effects of Adding Triamcinolone Acetonide to Conbercept Treatment for Refractory Diabetic Macular Edema (CONTE)
- Conditions
- Interventions
- First Posted Date
- 2020-11-13
- Last Posted Date
- 2020-11-17
- Target Recruit Count
- 50
- Registration Number
- NCT04627402
- Locations
- 🇨🇳
Zhongshan Opthalmic Center, Guangzhou, Guangdong, China
Application of Intravitreal Conbercept Injection as a Primary Treatment for Exudative Circumscribed Choroidal Haemangioma
- First Posted Date
- 2019-06-04
- Last Posted Date
- 2019-06-04
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 50
- Registration Number
- NCT03973125
- Locations
- 🇨🇳
Kunbei Lai, Guangzhou, Guangdong, China
PRP vs PRP+IVC for Severe nPDR
- Conditions
- Interventions
- First Posted Date
- 2019-03-05
- Last Posted Date
- 2019-03-05
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT03863535
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China
Safety and Effectiveness of Intravitreal Conbercept for Exudative Circumscribed Choroidal Haemangioma
- First Posted Date
- 2018-06-27
- Last Posted Date
- 2018-06-27
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 50
- Registration Number
- NCT03571282
- Locations
- 🇨🇳
Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, Guangdong, China
Intravitreal Conbercept After Vitrectomy
- Conditions
- Interventions
- First Posted Date
- 2018-02-08
- Last Posted Date
- 2019-04-30
- Lead Sponsor
- Tianjin Medical University Eye Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT03426540
The Efficacy Assessment of Intravitreal Injection of Conbercept in Patients With Polypoidal Choroidal Vasculopathy (PCV)
- First Posted Date
- 2017-05-19
- Last Posted Date
- 2017-07-19
- Lead Sponsor
- Chengdu Kanghong Biotech Co., Ltd.
- Target Recruit Count
- 300
- Registration Number
- NCT03159884
- Locations
- 🇨🇳
The Scond Xiangya Hospital of Central South University, Changsha, China
🇨🇳Beijing Tongren Hospital,Cmu, Beijing, China
🇨🇳Tianjin Medical University Eye Hospital, Tianjin, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.